John Eden

Dr. John Eden

Department of Reproductive Endocrinology, The University of New South Wiles, Sydney, Australia

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2003 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
PDF file
KWKaren E. Willetts
Karen E. Willetts
AEAbie Ekangaki
Abie Ekangaki
JEJohn Eden
John Eden

23 July 2003 in BJU International
Verified
Journal Article
Open access
PDF file
KWK.E. Willetts
K.E. Willetts
MCM.S. Clements
M.S. Clements
SCS. Champion
S. Champion
SES. Ehsman
S. Ehsman
JEJohn Eden
John Eden
OBJECTIVE: To compare the effect of a Serenoa repens extract with placebo for symptoms of benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: In a double‐blind placebo‐controlled randomized trial between January 1999 and March 2000, 100 men with symptoms of BPH, aged < 80 years, with a maximum urinary flow rate of 5–15 mL/s for a voiding volume of 150 mL, were randomly and equally allocated to 320 mg S. repens extract or placebo (paraffin oil). The main outcome measures were the International Prostate Symptom Score (IPSS), peak urinary flow rate, and the Rosen International Index of Erectile Function (IIEF) questionnaire. RESULTS: There was no significant difference between the treatments over the 12 weeks of the study in the IPSS, peak urinary flow rate or for the IIEF questionnaire. CONCLUSIONS: During the trial all participants had some improvement in their symptoms of BPH but there was no significant beneficial effect of this S. repens extract over placebo in this 12‐week trial.

1 June 2012 in Maturitas
Verified
Journal Article
Closed access
JEJohn Eden
John Eden

1 January 2000 in BioFactors
Verified
Journal Article
Closed access
PDF file
RMR. Mackey
R. Mackey
AEA. Ekangaki
A. Ekangaki
JEJohn Eden
John Eden

20 August 2007 in Medical Journal of Australia
Verified
Journal Article
Closed access
JEJohn Eden
John Eden
NHNeville F Hacker
Neville F Hacker
MFMichael Fortune
Michael Fortune
We describe three women who developed endometrial cancer after taking "bioidentical" hormone replacement therapy (HRT) to relieve menopausal symptoms. Although pharmaceutical HRT is a well established and tested therapy, little is known about the quality control, safety and efficacy of bioidentical HRT. Women should be advised to avoid bioidentical HRT, and those who continue to use it should receive regular endometrial surveillance.

1 July 2010 in Menopause
Verified
Journal Article
Closed access
JEJohn Eden
John Eden
The aim of this narrative review was to evaluate the role of cancer stem cells (CSCs) and sex steroids in the pathophysiology of human breast cancer. A key-word search was performed using the Scopus database. Preference was given to studies using human cells and tissues. Long-term estrogen-progestin hormone therapy is known to increase breast cancer risk, although the mechanisms are poorly understood. In the last few years, it has become clear that many human breast cancers contain CSCs, which may be responsible for much of the tumor's malignant behavior. Very recently, the impact of estrogen, progesterone, and progestins on breast CSCs and their progeny has been studied and clarified. Most breast CSCs are estrogen receptor negative and progesterone receptor negative, although some intermediary progenitor forms have hormone receptors, especially progesterone receptor. Most mature human breast cancer cellsare estrogen receptor positive and can thus be stimulated by estrogen. Breast CSCs usually elaborate CD44+,CD24j/low and/or ALDEFLUOR+ cell markers and are lineage markers negative. One of the main roles of progesterone and progestin seems to be on certain breast cancer stem intermediate forms, inducing them to revert back to a more primitive breast CSC form. As the pathophysiology of human breast CSC is clarified, it is probable that this will lead to novel, effective breast cancer treatments and, perhaps, new breast cancer preventive agents. This research may also lead to safer hormone therapy regimens.